Capstone Financial Advisors Inc. Has $498,000 Holdings in Abbott Laboratories (NYSE:ABT)

Capstone Financial Advisors Inc. lowered its stake in Abbott Laboratories (NYSE:ABTFree Report) by 2.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,753 shares of the healthcare product maker’s stock after selling 81 shares during the period. Capstone Financial Advisors Inc.’s holdings in Abbott Laboratories were worth $498,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Three Seasons Wealth LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth about $1,428,000. Kelly Financial Services LLC acquired a new position in shares of Abbott Laboratories during the 1st quarter worth about $216,000. Voleon Capital Management LP acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $273,000. Bank Pictet & Cie Europe AG lifted its position in shares of Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker’s stock worth $17,274,000 after purchasing an additional 2,774 shares during the last quarter. Finally, Edge Financial Advisors LLC lifted its position in shares of Abbott Laboratories by 3.3% during the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker’s stock worth $336,000 after purchasing an additional 81 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.9%

Shares of ABT opened at $127.32 on Monday. The company has a market capitalization of $221.60 billion, a P/E ratio of 15.95, a PEG ratio of 2.41 and a beta of 0.70. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a one year low of $107.11 and a one year high of $141.23. The business’s 50 day simple moving average is $131.78 and its 200-day simple moving average is $130.61.

Abbott Laboratories (NYSE:ABTGet Free Report) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting the consensus estimate of $1.26. The business had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%. Abbott Laboratories’s revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.14 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be issued a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $2.36 annualized dividend and a yield of 1.9%. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Analyst Ratings Changes

Several research firms recently weighed in on ABT. BTIG Research cut their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, July 18th. Barclays boosted their price objective on Abbott Laboratories from $158.00 to $159.00 and gave the stock an “overweight” rating in a research report on Thursday, April 17th. Mizuho boosted their price objective on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 16th. Royal Bank Of Canada boosted their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 15th. Finally, Evercore ISI boosted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $144.47.

Get Our Latest Report on ABT

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Recommended Stories

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.